問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Digestive System Department

Division of General Internal Medicine

更新時間:2023-09-19

高嘉宏Kao, Jia-Horng
  • Principal Investigator
  • Clinical Trial Experience (year) -24 years -4 個月

篩選

List

106Cases

2020-01-01 - 2025-12-31

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting1Sites

Terminated1Sites

2020-05-01 - 2025-03-31

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting5Sites

2020-09-01 - 2024-07-05

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2020-11-06 - 2023-12-26

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2021-04-01 - 2029-09-13

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting3Sites

2023-01-05 - 2026-12-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2023-02-15 - 2025-06-30

Phase I

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting10Sites

2023-06-01 - 2026-12-31

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2026-01-01 - 2032-03-10

Phase III

Active
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease who are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes)
  • Condition/Disease

    Metabolic Dysfunction-Associated Steatotic Liver Disease

  • Test Drug

    Retatrutide (LY3437943) Tirzepatide (LY3298176)

Participate Sites
15Sites

Not yet recruiting8Sites

Recruiting7Sites

2023-11-09 - 2032-11-22

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites